Clinical trials of novel therapies offer very sick people hope, but trials of me-too drugs or drugs that have failed repeatedly waste patients' time for little gain and occasional harm, writes Gail McIntyre, chief scientific officer at Aravive. Cancer therapies should be moved to clinical development "only when there's a strong understanding of disease biology and substantial evidence that a drug has the potential to truly improve lives," and sponsors should ask themselves every step of the way whether they would want their loved ones to take the drug, McIntyre writes.
Opinion: Patients deserve better than "me-too" drugs
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.